COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,676 Articles (22,913 medRxiv, 8,763 bioRxiv)

Most recent first Previous |  Page 1089: Articles 10881-10890  | Next

Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies
Vogt, A.-C. S., Jörg, L., Martina, B., Krenger, P. S., Chang, X., Zeltins, A., Vogel, M., Mohsen, M. O., Bachmann, M. F.
10.1101/2021.12.20.473421 — Posted: 2021-12-22
Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by the N-terminal peptide of lactoferrin
Ohradanova-Repic, A., Gebetsberger, L., Tajti, G., Ondrovicova, G., Prazenicova, R., Skrabana, R., Barath, P., Stockinger, H., Leksa, V.
10.1101/2021.12.20.473447 — Posted: 2021-12-22
Immune escape of SARS-CoV-2 Omicron variant from mRNA vaccination-elicited RBD-specific memory B cells.
Sokal, A., Broketa, M., Meola, A., Barba-Spaeth, G., Fernandez, I., Fourati, S., Azzaoui, I., de La Selle, A., Vandenberghe, A., Roeser, A., Bouvier-Alias, M., Crickx, E., Languille, L., Michel, M., Godeau, B., Gallien, S., Melica, G., Nguyen, Y., Zarrouk, V., Canoui-Poitrine, F., Noizat-Pirenne, F., Megret, J., Pawlotsky, J.-M., Fillatreau, S., Simon-Loriere, E., Weill, J.-C., Reynaud, C.-A., Rey, F. A., Bruhns, P., Chappert, P., Mahevas, M.
10.1101/2021.12.21.473528 — Posted: 2021-12-22
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant
Edara, V.-V., Manning, K. E., Ellis, M., Lai, L., Moore, K. M., Foster, S. L., Floyd, K., Davis-Gardner, M. E., Mantus, G., Nyhoff, L. E., Bechnack, S., Alaaeddine, G., Naji, A., Samaha, H., Lee, M., Bristow, L., Hussaini, L., Ciric, C. R., Nguyen, P.-V., Gagne, M., Roberts-Torres, J., Henry, A. R., Godbole, S., Grakoui, A., Sexton, M., Piantadosi, A., Waggoner, J. J., Douek, D. C., Anderson, E. J., Rouphael, N., Wrammert, J., Suthar, M. S.
10.1101/2021.12.20.473557 — Posted: 2021-12-22
Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection.
Adhikari, A., Abayasingam, A., Rodrigo, C., Agapiou, D., Pandzic, E., Brasher, N. A., Fernando, B. S. M., Keoshkerian, E., Li, H., Kim, H. N., Lord, M., Popovic, G., Rawlinson, W., Mina, M., Post, J. J., Hudson, B., Gilroy, N., Bartlett, A. W., Ahlenstiel, G., Grubor-Bauk, B., Dwyer, D., Konecny, P., Lloyd, A. R., Martinello, M., Bull, R. A., Tedla, N.
10.1101/2021.12.21.473774 — Posted: 2021-12-22
Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants
Zhang, L., Dutta, S., Xiong, S., Chan, M., Chan, K. K., Fan, T. M., Bailey, K. L., Lindeblad, M., Cooper, L. M., Rong, L., Gugliuzza, A. F., Shukla, D., Procko, E., Rehman, J., Malik, A. B.
10.1101/2021.12.21.473668 — Posted: 2021-12-22
An in silico analysis of early SARS-CoV-2 variant B.1.1.529 (Omicron) genomic sequences and their epidemiological correlates
Kumar, A., Asghar, A., Singh, H. N., Faiq, M. A., Kumar, S., Narayan, R. K., Kumar, G., Dwivedi, P., Sahni, C., Jha, R. K., Kulandhasamy, M., Prasoon, P., Sesham, K., Kant, K., Pandey, S. N.
10.1101/2021.12.18.21267908 — Posted: 2021-12-22
Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant
Bekliz, M., Adea, K., Alvarez, C., Essaidi-Laziosi, M., Escadafal, C., Kaiser, L., Eckerle, I.
10.1101/2021.12.18.21268018 — Posted: 2021-12-22 Discussion: Onsite | Offsite
Structural flexibility of the SARS-CoV-2 genome relevant to variation, replication, pathogenicity, and immune evasion.
Patarca, R., Haseltine, W. A.
10.1101/2021.12.20.473542 — Posted: 2021-12-21
Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study
Hansen, C. H., Schelde, A. B., Moustsen-Helms, I. R., Emborg, H.-D., Krause, T. G., Moelbak, K., Valentiner-Branth, P., The Infectious Disease Preparedness Group at Statens Serum Institut
10.1101/2021.12.20.21267966 — Posted: 2021-12-21 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).